Title: Determinants of Oxygen Uptake (VO₂) Among Patients with CF-LVADs.

Purpose: Characterize individual components of VO₂ (cardiac output [Qc] and (A-V)O₂ difference) at rest and during submaximal and peak exercise among CF-LVAD patients.

Methods: Thirteen CF-LVAD participants (56±12 yrs, 12 male) and 9 healthy controls 42±12 yrs, 7 male) completed invasive cardiopulmonary exercise testing on a stationary upright cycle ergometer. Hemodynamic data and gas-exchange parameters were collected at rest, two submaximal levels of exercise below the ventilatory threshold, and peak workload. Swan-Ganz catheterization was performed to determine baseline hemodynamics. A conductance catheter was then used to calculate Qc at each stage of exercise. VO₂ was recorded on a breath-by-breath basis by indirect calorimetry. Blood pressure was continuously monitored by arterial line. Musculoskeletal performance was assessed by calculating the (A-V)O₂ difference at each stage of exercise.

Results: Cohort characteristics and baseline demographics are demonstrated in **table 1**. Peak VO₂ among CF-LVAD participants was severely reduced compared to healthy controls. When CF-LVAD participants were matched to healthy controls by workload according to VO₂ quartiles, the CF-LVAD participants had a hypotensive response to exercise, as well as a blunted rise in Qc, with modest increases only from rest to submaximal exercise (**figure 1**). As a result, (A-V)O₂ difference was higher for CF-LVAD participants than healthy controls at each VO₂ quartile.

Conclusion: Due to impairments in contractile reserve, CF-LVAD participants exhibit a greater $(A-V)O_2$ difference than healthy individuals when exercising at similar workloads.

Table 1: Baseline Demographics and Hemodyn	CF-LVAD	Healthy Control
	(N=13)	(N=9)
Demographics	((
Age, years	56±12	42±12
Male Sex, N (%)	12 (92)	7 (78)
Height, cm	178±9	176±10
Weight, kg	91±18	78±11
Body mass index, kg/m ²	28±5	25±2
Body surface area, m ²	2.1±0.3	1.95±0.19
Heart Failure Etiology	2.120.0	1.00±0.10
Ischemic, N (%)	6 (46)	
Nonischemic, N (%)	7 (54)	
LVAD Characteristics	, (01)	
Duration of support, months	20±22	
Heartmate II, N (%)	3 (23)	
Heartmate 3, N (%)	1 (8)	
Heartware VAD, N (%)	9 (69)	
Medications	- ()	
Beta-blocker, N (%)	5 (38)	
Angiotensin-converting-enzyme inhibitor, N (%)	7 (53)	
Angiotensin receptor blocker, N (%)	3 (23)	
Mineralocorticoid receptor antagonist, N (%)	5 (38)	
Baseline hemodynamics		
Heart rate, bpm	76±11	59±5
Systolic blood pressure, mmHg	108±23	128±10
Diastolic blood pressure, mmHg	81±9	72±12
Mean arterial pressure, mmHg	90±12	91±9
Right atrial pressure, mmHg	6±3	4±2
Systolic pulmonary arterial pressure, mmHg	29±7	24±2
Diastolic pulmonary arterial pressure, mmHg	13±5	9±3
Mean pulmonary arterial pressure, mmHg	19±5	13±3
Pulmonary capillary wedge pressure, mmHg	10±5	7±3
Pulmonary arterial saturation, (%)	65±6	73±3
Cardiac output (Fick), L/min	5.4±0.9	6.3±1.6
Cardiac index, L/min/m ²	2.8±0.8	3.2±0.8
Right Ventricular Afterload	2.010.0	J.Z_U.0
Pulmonary vascular resistance, Woods units	1.6±0.7	1.1±0.4
RV Systolic Function (contractility)	1.0±0.7	1.1±0.4
Preload recruitable stroke work, mmHg	7 ± 5	10 ± 3
dpdt _{max} , mmHg/sec RV Diastolic Function	235±72	230±21
	E0 101	10:10
Tau, msec	58±21	40±12
dpdt _{min} , mmHg/sec	-195±66	-190±21

Table 1: Baseline Demographics and Hemodynamic Characteristics

